Clinical Trial

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Name: A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer — clinical trial record (NCT06921837)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2025-04-04; most recent amendment 2026-01-23.

Status change: Not Yet Recruiting → Recruiting 2025-05-02

Trial Details

NCT Number	NCT06921837
Lead Sponsor	Bolt Biotherapeutics, Inc.
Conditions	Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma
Enrollment	122 participants
Start Date	2025-05-26
Primary Completion	2027-05 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-01-27